X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (711) 711
sclerostin (669) 669
humans (431) 431
osteoporosis (388) 388
endocrinology & metabolism (380) 380
animals (365) 365
postmenopausal women (257) 257
female (247) 247
mice (223) 223
male (219) 219
orthopedics (202) 202
density (187) 187
bones (186) 186
sclerostin antibody (173) 173
genetic markers (169) 169
analysis (160) 160
osteocytes (157) 157
bone (154) 154
osteogenesis (149) 149
sost protein (145) 145
expression (138) 138
mineral density (130) 130
article (129) 129
middle aged (129) 129
wnt (129) 129
bone-mineral density (127) 127
parathyroid-hormone (122) 122
medicine & public health (118) 118
osteoblasts (118) 118
aged (114) 114
sost (110) 110
bone density (109) 109
fractures (109) 109
mass (108) 108
bone morphogenetic proteins - metabolism (104) 104
bone morphogenetic proteins - blood (103) 103
bone-formation (102) 102
cell biology (102) 102
parathyroid hormone (99) 99
endocrinology (98) 98
bone and bones - metabolism (96) 96
differentiation (89) 89
osteocytes - metabolism (88) 88
proteins (88) 88
gene expression (86) 86
signal transduction (84) 84
osteocyte (83) 83
van-buchem-disease (83) 83
strength (82) 82
bone growth (81) 81
adult (79) 79
bone mineral density (76) 76
serum sclerostin (75) 75
rheumatology (74) 74
wnt protein (74) 74
rats (73) 73
research (73) 73
sost gene (73) 73
cells (72) 72
gene (72) 72
bone density - drug effects (71) 71
bone resorption (71) 71
bmp antagonist (70) 70
bone turnover (70) 70
in-vivo (68) 68
romosozumab (68) 68
biochemistry & molecular biology (66) 66
osteoblast (66) 66
osteoblasts - metabolism (66) 66
osteoporosis - drug therapy (66) 66
physiological aspects (66) 66
bone mass (65) 65
bone remodeling (65) 65
antibodies (64) 64
collagen (64) 64
denosumab (63) 63
beta-catenin (61) 61
biomarkers - blood (60) 60
health aspects (60) 60
osteogenesis - drug effects (60) 60
glycoproteins - metabolism (58) 58
bone density conservation agents - therapeutic use (56) 56
biocompatibility (55) 55
bone formation (55) 55
bone morphogenetic proteins - genetics (55) 55
protein (54) 54
care and treatment (53) 53
metabolism (53) 53
medicine, research & experimental (52) 52
viral antibodies (52) 52
wnt signaling pathway (52) 52
disease (51) 51
immunohistochemistry (51) 51
disease models, animal (50) 50
pharmacology & pharmacy (50) 50
mineralization (49) 49
bone density - physiology (48) 48
bone remodeling - physiology (48) 48
aged, 80 and over (47) 47
apoptosis (47) 47
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (919) 919
German (7) 7
French (3) 3
Korean (2) 2
Chinese (1) 1
Czech (1) 1
Russian (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Journal Article
Journal of Bone and Mineral Research, ISSN 0884-0431, 11/2010, Volume 25, Issue 11, pp. 2412 - 2418
Journal Article
Journal Article
Journal of Bone and Mineral Research, ISSN 0884-0431, 12/2019, Volume 34, Issue 12, pp. 2301 - 2310
ABSTRACT Sclerostin antibody (Scl‐Ab) is an anabolic bone agent that has been shown to increase bone mass in clinical trials of adult diseases of low bone... 
ANABOLIC EFFECT | OSTEOGENESIS IMPERFECTA | SCLEROSTIN ANTIBODY | CRANIAL MORPHOLOGY | VASCULARITY
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 02/2014, Volume 54, Issue 2, pp. 168 - 178
Romosozumab (formerly AMG 785/CDP7851) is a monoclonal antibody that blocks sclerostin from inhibiting osteoblast maturation and function. This double‐blind,... 
CDP7851 | romosozumab | bone mineral density | pharmacodynamics | pharmacokinetics | AMG 785 | sclerostin | Pharmacodynamics | Sclerostin | Bone mineral density | Romosozumab | Pharmacokinetics | PROTEIN | STRENGTH | OSTEOPOROSIS | DENSITY | GENE | PHARMACOLOGY & PHARMACY | SOST | Collagen Type I - blood | Peptides - blood | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Osteoporosis, Postmenopausal - metabolism | Male | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal, Humanized - pharmacokinetics | Antibodies, Monoclonal, Humanized - pharmacology | Peptide Fragments - blood | Aged, 80 and over | Female | Bone Density Conservation Agents - pharmacokinetics | Antibodies, Monoclonal, Humanized - adverse effects | Bone Density Conservation Agents - adverse effects | Double-Blind Method | Drug Administration Schedule | Antibodies, Monoclonal - pharmacology | Antibodies, Monoclonal - pharmacokinetics | Lumbar Vertebrae - drug effects | Procollagen - blood | Bone Density Conservation Agents - administration & dosage | Osteoporosis, Postmenopausal - drug therapy | Bone Density Conservation Agents - pharmacology | Bone Density - drug effects | Osteoporosis, Postmenopausal - blood | Antibodies, Monoclonal - administration & dosage | Aged | Viral antibodies | Antibodies | Care and treatment | Dosage and administration | Postmenopausal women | Research | Osteoporosis | Men
Journal Article
Journal of Bone and Mineral Research, ISSN 0884-0431, 04/2009, Volume 24, Issue 4, pp. 578 - 588
The development of bone-rebuilding anabolic agents for potential use in the treatment of bone loss conditions, such as osteoporosis, has been a long-standing... 
Journal Article
Journal of Bone and Mineral Research, ISSN 0884-0431, 04/2009, Volume 24, Issue 4, pp. 578 - 588
Journal Article